Merck & Co., Inc. Furnishes Third-Quarter 2025 Financial Results
Summary
Merck & Co., Inc. furnished its third-quarter 2025 financial results on October 30, 2025, via an earnings press release (Ex. 99.1). The company reported total worldwide sales of $17.3 billion, marking a 4% increase from the third quarter of 2024. GAAP EPS was $2.32, while Non-GAAP EPS reached $2.58, which included a $0.10 per share charge for a milestone payment to LaNova. * KEYTRUDA sales grew 10% to $8.1 billion. * WINREVAIR sales were $360 million, a 141% increase. * Received FDA approval for KEYTRUDA QLEX Injection for subcutaneous use across all solid tumor indications. * Animal Health sales grew 9% to $1.6 billion.
Why It Matters
The reported sales growth, particularly for KEYTRUDA and WINREVAIR, along with the FDA approval of KEYTRUDA QLEX Injection (all via Ex. 99.1), indicates strong performance in key product areas and significant pipeline advancements, which are material signals for investors.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how MRK traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View MRK Charts on TradingViewAffiliate link
Key Quote
“by Merck & Co., Inc. on October 30, 2025, regarding earnings for the third quarter of 2025, attached as Exhibit 99.1.”
— From Item 2.02
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000310158
- Filing Date
- Thursday, October 30, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive